Researcher Diana J. Azzam and her team conducted a study on the feasibility of functional precision medicine (FPM) in treating relapsed or refractory pediatric cancers. By combining genomic profiling with drug sensitivity testing, FPM identified personalized treatment options for children who had exhausted standard therapies, with results delivered in clinically actionable timeframes. The study demonstrated promising outcomes, with patients receiving FPM-guided treatments showing improved progression-free survival, highlighting FPM’s potential to transform pediatric cancer care.

We are proud to partner with these exceptional researchers and institutions to make these groundbreaking trials possible. We invite you to explore this page to learn about all the incredible, life-changing research funded by the Live Like Bella Pediatric Cancer Research Initiative, working toward making pediatric cancer a treatable and curable disease.